Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2019, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 38, 11, 2, 45, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.
Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
- The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Graft Versus Host Disease (GVHD) - Overview
Graft Versus Host Disease (GVHD) - Therapeutics Development
Graft Versus Host Disease (GVHD) - Therapeutics Assessment
Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
Graft Versus Host Disease (GVHD) - Drug Profiles
Graft Versus Host Disease (GVHD) - Dormant Projects
Graft Versus Host Disease (GVHD) - Discontinued Products
Graft Versus Host Disease (GVHD) - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 8: Number of Products under Development by Universities/Institutes, H2 2019
Table 9: Products under Development by Companies, H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 15: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 16: Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Table 17: Products under Development by Universities/Institutes, H2 2019
Table 18: Number of Products by Stage and Target, H2 2019
Table 19: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 20: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 21: Number of Products by Stage and Mechanism of Action, H2 2019
Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 25: Number of Products by Stage and Route of Administration, H2 2019
Table 26: Number of Products by Stage and Molecule Type, H2 2019
Table 27: Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2019
Table 28: Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H2 2019
Table 29: Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2019
Table 30: Graft Versus Host Disease (GVHD) - Pipeline by Alpine Immune Sciences Inc, H2 2019
Table 31: Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H2 2019
Table 32: Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H2 2019
Table 33: Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H2 2019
Table 34: Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, H2 2019
Table 35: Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, H2 2019
Table 36: Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H2 2019
Table 37: Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
Table 38: Graft Versus Host Disease (GVHD) - Pipeline by Biocon Ltd, H2 2019
Table 39: Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2019
Table 40: Graft Versus Host Disease (GVHD) - Pipeline by BioIncept LLC, H2 2019
Table 41: Graft Versus Host Disease (GVHD) - Pipeline by BlueRock Therapeutics, H2 2019
Table 42: Graft Versus Host Disease (GVHD) - Pipeline by Boryung ViGenCell Inc, H2 2019
Table 43: Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 44: Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, H2 2019
Table 45: Graft Versus Host Disease (GVHD) - Pipeline by Celgene Corp, H2 2019
Table 46: Graft Versus Host Disease (GVHD) - Pipeline by Cellect Biotechnology Ltd, H2 2019
Table 47: Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc, H2 2019
Table 48: Graft Versus Host Disease (GVHD) - Pipeline by Cellix Bio Pvt Ltd, H2 2019
Table 49: Graft Versus Host Disease (GVHD) - Pipeline by CheckPoint Immunology Inc, H2 2019
Table 50: Graft Versus Host Disease (GVHD) - Pipeline by Clinigen Group Plc, H2 2019
Table 51: Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd, H2 2019
Table 52: Graft Versus Host Disease (GVHD) - Pipeline by CTI BioPharma Corp, H2 2019
Table 53: Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc, H2 2019
Table 54: Graft Versus Host Disease (GVHD) - Pipeline by Cytopeutics Pte Ltd, H2 2019
Table 55: Graft Versus Host Disease (GVHD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Table 56: Graft Versus Host Disease (GVHD) - Pipeline by Dualogics Corp, H2 2019
Table 57: Graft Versus Host Disease (GVHD) - Pipeline by Eli Lilly and Co, H2 2019
Table 58: Graft Versus Host Disease (GVHD) - Pipeline by Elsalys Biotech SA, H2 2019
Table 59: Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc, H2 2019
Table 60: Graft Versus Host Disease (GVHD) - Pipeline by Enlivex Therapeutics Ltd, H2 2019
List of Figures
Figure 1: Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
